TY  - CHAP
AU  - Lucia Messingerova
AU  - Denisa Imrichova
AU  - Martina Coculova
AU  - Marian
Zelina
AU  - Lucia Pavlikova
AU  - Helena Kavcova
AU  - Mario Seres
AU  - Viera
Bohacova
AU  - Boris Lakatos
AU  - Zdena Sulova
AU  - Albert Breier
ED  - Ota Fuchs
Y1  - 2016-09-07
PY  - 2016
T1  - Different Mechanisms of Drug Resistance in Myelodysplastic Syndromes and Acute Myeloid Leukemia
N2  - This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML.
BT  - Myelodysplastic Syndromes
SP  - Ch. 7
UR  - https://doi.org/10.5772/63483
DO  - 10.5772/63483
SN  - 978-953-51-2587-7
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-26
ER  -